A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis

Area of Science:

• Molecular Biology
• Oncology
• Hepatology

Background:

• Hepatitis B Virus (HBV) drives liver carcinogenesis through epigenetic alterations.
• Epitranscriptomic regulation, including m6A modification, is implicated in cancer development.
• The role of AlkB Homolog 5 (ALKBH5) in HBV-related hepatocellular carcinoma (HCC) is not well understood.

Purpose of the Study:

• To investigate the function, clinical significance, and regulatory mechanism of ALKBH5 in HBV-associated HCC.
• To explore the relationship between HBx, ALKBH5, and liver carcinogenesis.

Main Methods:

• Expression analysis of ALKBH5 in HBV-HCC tissues and cell lines using RT-qPCR, Western blot, and immunohistochemistry.
• Functional assessment of ALKBH5 using knockdown and overexpression systems in vitro and in vivo.
• Mechanistic studies involving ChIP-qPCR, MeRIP-qPCR, and Actinomycin D to elucidate the HBx-ALKBH5 interaction and m6A modification.

Main Results:

• ALKBH5 expression is elevated in HBV-HCC tissues and correlates with poor prognosis.
• HBx protein induces ALKBH5 expression via H3K4me3 modification of the ALKBH5 promoter in a WDR5-dependent manner.
• ALKBH5 demethylates HBx mRNA, enhancing its stability and expression, thereby promoting tumor growth and migration.

Conclusions:

• HBx and ALKBH5 form a positive feedback loop that contributes to HBV-induced liver carcinogenesis.
• Targeting ALKBH5 presents a potential therapeutic strategy for HBV-HCC.